U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07011732) titled 'A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)' on June 02.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Study Start Date: July 18
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Intervention:
DRUG: Xanomeline/Trospium Chloride Capsule
Specified dose on specified days
DRUG: Xanomeline Enteric Capsule
Specified dose on specified days
DRUG: Placebo
Specified dose on specified days
Recruitment S...